首页> 外文期刊>Current diabetes reviews >Association between Statin Use and Poor Outcomes in COVID-19 Patients with Diabetes Mellitus: A Systematic Review
【24h】

Association between Statin Use and Poor Outcomes in COVID-19 Patients with Diabetes Mellitus: A Systematic Review

机译:他汀类药物使用与 COVID-19 糖尿病患者不良预后之间的关联:系统评价

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and Aims: Diabetes mellitus, cardiovascular diseases, obesity, and dyslipidaemia are considered risk factors for more severe forms of COVID-19 infection. Statins have been widely used in such patients to prevent the occurrence of cardiovascular events and the associated mortality. However, statin use has been suggested to promote a more severe form of infection. This review aims to investigate the association between statin use and poor outcomes in COVID-19 patients with diabetes. Methods: Literature search was performed in PubMed, CENTRAL, Scopus, and pre-print databases (MedRxiv and BioRxiv), and studies published up to March 6th, 2021 have been reviewed. Selected studies were then assessed for risk of bias with the Newcastle Ottawa Scale. Result: Four studies were included in the final analysis; all were retrospective studies. Two studies reported a decreased risk of mortality with statin use, while one study reported opposite findings. The other one did not find a significant association between statin use and poor COVID-19 outcomes. Conclusion: Available data suggest that statins may be safely administered to diabetic COVID-19 patients as the majority of evidence signifies statins to confer benefits and improve clinical outcomes in COVID-19 patients.
机译:背景和目标:糖尿病、心血管疾病、肥胖和血脂异常被认为是更严重形式的 COVID-19 感染的危险因素。他汀类药物已广泛用于此类患者,以预防心血管事件的发生和相关死亡率。然而,有人建议使用他汀类药物会促进更严重的感染。本综述旨在探讨他汀类药物使用与COVID-19糖尿病患者不良结局之间的关联。方法:在PubMed、CENTRAL、Scopus和预印本数据库(MedRxiv和BioRxiv)中进行文献检索,并回顾截至2021年3月6日发表的研究。然后使用纽卡斯尔渥太华量表评估选定的研究的偏倚风险。结果:最终分析纳入4项研究;所有研究均为回顾性研究。两项研究报告使用他汀类药物可降低死亡风险,而一项研究报告了相反的结果。另一项研究没有发现他汀类药物的使用与不良的COVID-19结局之间存在显着关联。结论:现有数据表明,他汀类药物可以安全地用于糖尿病 COVID-19 患者,因为大多数证据表明他汀类药物可以带来益处并改善 COVID-19 患者的临床结果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号